Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Unknown × Rivaroxaban × Clear all

Phase

Phase 4 2 Phase 3 2 Phase NA 1 Phase 2/3 1 Phase 2 1 Phase 1 1

Status

Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Cisplatin 20 Docetaxel 19 Capecitabine 19 Oxaliplatin 14 Drug Therapy 14 Cyclophosphamide 14 Paclitaxel 12 Fluorouracil 12 Radiotherapy 11 apatinib 9 Doxorubicin 9 Decitabine 9 Methotrexate 8 Gemcitabine 8 Epirubicin 8 Carboplatin 8 sintilimab 6 Etoposide 6 Cytarabine 6 Busulfan 6 camrelizumab 5 anlotinib 5 XELOX 5 Sorafenib 5 Radiation 5 Pemetrexed 5 Neoadjuvant Therapy 5 Leucovorin 5 Idarubicin 5 Dexamethasone 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03428373 2024-02-29

RithMM

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2/3 Unknown

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡